Article
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2024
Kitagawa Shingo, Zenke Yoshitaka, Taki Tetsuro, Aokage Keiju, Sakai Tetsuya, Shibata Yuji, Izumi Hiroki, Nosaki Kaname, Umemura Shigeki, Matsumoto Shingo, Yoh Kiyotaka, Sakamoto Naoya, Sakashita Shingo, Kojima Motohiro, Tsuboi Masahiro, Goto Koichi, Ishii Genichiro
Abstract excerpt
OBJECTIVES: This study extracted clinicopathological features associated with recurrence and evaluated the tumor microenvironment in consecutive cases with resected pathological stage II-III epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (EGFR-mt). METHODS: Between January 2008 and November 2018, we retrospectively reviewed 387 consecutive patients with pathological stage II-III lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
